Small-cap stock Godavari Biorefineries’ shares hit their upper circuit on Tuesday, 22 July 2025, after the company secured a patent for its “novel anti-cancer molecule” from China’s patent and trademark office, according to an exchange filing.
“Godavari Biorefineries Ltd, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China’s patent and trademark office, for its novel anti-cancer molecule — HYDROXY-1,4-NAPHTHALENEDIONE,” the company informed the BSE through the filing.
Godavari Biorefineries is a major producer of ethanol and ethanol-based chemicals in India. The company manufactures bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power, according to the official website.
(This is a developing story. Please check back for updates.)
Read all stories by Anubhav Mukherjee
Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
